Product Detail

 Home / Product Detail

Febuxostat-40

Febuxostat 40 mg Tablets

Febuxostat, is a medication used in the treatment of chronic  gout and  hyperuricemia. There are concerns about more heart related deaths with febuxostat compared to  allopurinol. It inhibits  xanthine oxidase, thus reducing production of  uric acid in the body.

Medical uses

Febuxostat is used to treat chronic  gout and  hyperuricemia. Febuxostat is typically only recommended in those who cannot tolerate allopurinol.  National Institute for Health and Clinical Excellence concluded that febuxostat is more effective than standard doses of  allopurinol, but not more effective than higher doses of allopurinol.

Side effects

The adverse effects associated with febuxostat therapy include nausea, diarrhea, arthralgia, headache, increased hepatic serum enzyme levels and rash.

On 15 November 2017, the FDA issued a safety alert indicating that the preliminary results from a safety clinical trial showed an increased risk of heart-related death with febuxostat compared to allopurinol. The FDA required Takeda to conduct this safety study when the medicine was approved in 2009. The febuxostat drug labels already carry a warning and precaution about cardiovascular events because the clinical trials conducted before approval showed a higher rate of heart-related problems in patients treated with febuxostat compared to allopurinol. These problems included heart attacks, strokes, and heart-related deaths. As a result, the FDA required an additional safety clinical trial after the drug was approved and on the market to better understand these differences, and that trial was finished recently. The safety trial was conducted in over 6,000 patients with gout treated with either febuxostat or allopurinol. The primary outcome was a combination of heart-related death, non-deadly heart attack, non-deadly stroke, and a condition of inadequate blood supply to the heart requiring urgent surgery. The preliminary results show that overall, febuxostat did not increase the risk of these combined events compared to allopurinol. However, when the outcomes were evaluated separately, febuxostat showed an increased risk of heart-related deaths and death from all causes.

Drug interactions

Febuxostat is contraindicated with concomitant use of  theophylline and  chemotherapeutic agents, namely  azathioprine and  6-mercaptopurine, because it could increase blood plasma concentrations of these drugs, and therefore their toxicity.

Mechanism of action

Febuxostat is a non-purine-selective inhibitor of  xanthine oxidase. It works by non-competitively blocking the  molybdenum pterin center which is the active site on xanthine oxidase. Xanthine oxidase is needed to successively oxidize both  hypoxanthine and  xanthine to uric acid. Hence, febuxostat inhibits xanthine oxidase, therefore reducing production of uric acid. Febuxostat inhibits both oxidized as well as reduced form of xanthine oxidase because of which febuxostat cannot be easily displaced from the molybdenum pterin site.